Biosimilar monoclonal antibodies
Biosimilars and biobetters industry is likely to become a lot more dynamic and strategic than we’ve seen with small molecule generics; there will begin to become a premium on flexibility and willingness to take chances in an ever-shifting competitive and regulatory environment. The approval of the first biosimilar in the US is expected to save the healthcare industry and patients $5.7 billion over the next decade. The US biosimilars market is expected to reach $2 billion by 2018 and with the first biosimilar approved recently in America, this is an exciting time for the biosimilar field with approval in the US expected to increase during the next ten years. The regulatory landscape is evolving rapidly so it is important to understand the developments in the biosimilar guideline framework and the cohesion in legislation between the US and Europe. Key factors driving market growth include patent expiries of key biological drugs, cost containment measures from governments, aging population, and supporting legislations. The recent establishment of regulatory guidelines for biosimilars in the US is expected to add further momentum to the growth of the global biosimilars market. Increasing pressure from governments and insurers for greater biologic competition, there exists an incredible opportunity for biosimilar producers to capitalise on what is set to become the fastest growing sector of the pharmaceutical industry.
- Biosimilars and Non-Originator Biologics
- Biosimilar Regime
- Use of Autologous IL-1ra and Other Cytokines in Orthopedics
- Technological Platform for Innovative and Biosimilar Antibodies
- Biosimilars and Non-Originator Biologics
- Novel Cell-Based Bioassays for Analysis of mAb Fc Effector and Immune Checkpoint
Related Conference of Biosimilar monoclonal antibodies
5th International conference on Vaccines, Vaccination and Immunization
Biosimilar monoclonal antibodies Conference Speakers
Recommended Sessions
- Anti-Cancer Antibodies
- Antibodies Immunogenecity
- Antibodies: Medical Applications
- Antibodies:Infectious Diseases
- Antibody Conjugate Therapeutics: Challenges and Potential
- Antibody Drug Therapy
- Antibody Engineering
- Antibody Fragment Engineering and Applications in Diagnosis and Therapeutics
- Antibody Humanization Technologies
- Auto Antibodies
- Autoimmune Antibodies
- Bio therapeutics : Early Analytical Development
- Biomarkers Development
- Biosimilar monoclonal antibodies
- Biotherapeutics Antibody for the Treatment of Solid Cancers
- Biotherapeutics: Novel Formulation and Delivery Approaches
- Cancer Immune therapy
- Emerging Protein Bio therapeutics
- Immunotherapy and Immune Checkpoints
- Monoclonal Antibody Therapy
- Next-Generation Sequencing (NGS) In Antibody Discovery and Engineering: Overview and Applications
Related Journals
Are you interested in
- Cancer Immunology and Immunotherapy - IMMUNOLOGY 2024 (Spain)
- Cell & Plant Biology - IMMUNOLOGY 2024 (Spain)
- Cell Biology - IMMUNOLOGY 2024 (Spain)
- CELL, ANIMAL & PLANT BIOLOGY - IMMUNOLOGY 2024 (Spain)
- Clinical Immunology & Current & Future Research - IMMUNOLOGY 2024 (Spain)
- Immune System - IMMUNOLOGY 2024 (Spain)
- Immuno informatics & Systems immunology - IMMUNOLOGY 2024 (Spain)
- Immuno-Genetics - IMMUNOLOGY 2024 (Spain)
- Immunogenetics - IMMUNOLOGY 2024 (Spain)
- Immunohistochemistry - IMMUNOLOGY 2024 (Spain)
- Immunology - IMMUNOLOGY 2024 (Spain)
- Immunotherapy - IMMUNOLOGY 2024 (Spain)
- Nutritional Immunology - IMMUNOLOGY 2024 (Spain)
- OncoImmunology - IMMUNOLOGY 2024 (Spain)
- Pediatric and Neonatal Immunology - IMMUNOLOGY 2024 (Spain)
- Reproductive Immunology - IMMUNOLOGY 2024 (Spain)
- Transplantation and Computational Immunology - IMMUNOLOGY 2024 (Spain)
- Vaccines & Immunization - IMMUNOLOGY 2024 (Spain)
- Virology and infectious diseases - IMMUNOLOGY 2024 (Spain)